Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Emergent BioSolutions Inc. on August 24, 2010. The filing reports a corporate governance event regarding the appointment of a new director to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of John E. Niederhuber, M.D., as a Class III director on August 24, 2010. Dr. Niederhuber is an independent director under New York Stock Exchange rules and will stand for election at the 2012 annual meeting of stockholders. The filing confirms there are no related party transactions or special compensatory arrangements associated with this appointment.
Outlook and Management Commentary
Management commentary is limited to the background of the new director. Dr. Niederhuber joined Inova Health System in August 2010 as Executive Vice President and CEO of the Inova Institute for Translational Research and Personalized Medicine. He also serves as an adjunct investigator at the National Cancer Institute (NCI). Previously, he served as the director of NCI from 2005 to July 2010 and held leadership roles at the University of Wisconsin Comprehensive Cancer Center, Stanford University, Johns Hopkins University, and the University of Michigan.
Key Facts for Investor Verification
- John E. Niederhuber, M.D., was appointed to the Board of Directors on August 24, 2010.
- Dr. Niederhuber is classified as an independent director.
- He will be subject to election by stockholders at the 2012 annual meeting.
- No related party transactions or special compensation arrangements exist regarding this appointment.
- This filing contains no financial performance data or forward-looking guidance.